Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

NCT05411380 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Tucidinostat
DRUG: Capecitabine
DRUG: Endocrine Therapy

Sponsor

wang shusen